KC
ALXN

Kepos Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Kepos Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10,049
Closed -$1.09M – 343
2019
Q4 		$1.09M Buy
+10,049
New +$1.07M 0.1% 109
2019
Q3 		– Sell
-20,749
Closed -$2.72M – 413
2019
Q2 		$2.72M Sell
20,749
-26,064
-56% -$3.36M 0.28% 73
2019
Q1 		$6.33M Buy
46,813
+8,273
+21% +$1.03M 0.47% 46
2018
Q4 		$3.75M Buy
+38,540
New +$4.56M 0.29% 105
2018
Q3 		– Sell
-27,805
Closed -$3.45M – 439
2018
Q2 		$3.45M Sell
27,805
-4
-0% -$467 0.18% 130
2018
Q1 		$3.1M Buy
27,809
+21,376
+332% +$2.56M 0.18% 118
2017
Q4 		$769K Buy
+6,433
New +$783K 0.07% 151

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Kepos Capital's ALXN Position: Q1 2020 in Review

Kepos Capital sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 10,049 shares — an estimated $1.09M sold.

Kepos Capital first reported a position in ALXN in Q4 2017 and held it in 7 quarters. The position peaked at $6.33M in Q1 2019. 653 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

  • Kepos Capital reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Kepos Capital sold 10,049 Alexion Pharmaceuticals shares in Q1 2020, an estimated $1.09M.
  • Kepos Capital first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 7 quarters.
  • Kepos Capital's Alexion Pharmaceuticals position peaked at $6.33M in Q1 2019.
  • 653 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Kepos Capital's 13F filing for Q1 2020, filed 12 May 2020.